Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Choroid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Choroid. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-003329-40 Sponsor Protocol Number: 15-API-01 Start Date*: 2017-09-19
    Sponsor Name:CHU de Nice
    Full Title: Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008773 Choroid melanoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022687-12 Sponsor Protocol Number: STREAM Start Date*: 2011-03-17
    Sponsor Name:Universitätsklinikum Essen
    Full Title: A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma)
    Medical condition: choroid melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008773 Choroid melanoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011751-46 Sponsor Protocol Number: IC 2009-01 Start Date*: 2009-10-06
    Sponsor Name:INSTITUT CURIE
    Full Title: Etude de phase II monocentrique associant Bevacizumab et Temozolomide chez des patients atteints de mélanome uvéal en première ligne métastatique.
    Medical condition: Mélanome uvéal métastatique.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027151 Melanoma of choroid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005945-39 Sponsor Protocol Number: HLS03/2007 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Phase II open label study of Pegaptanib sodium on patients with subfoveal choroidal neovascularization caused by pathologic myopia.
    Medical condition: Patients with choroidal neovascularization secondary to pathologic myopia.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060823 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002424-42 Sponsor Protocol Number: 2006-002 Start Date*: 2006-03-20
    Sponsor Name:OSPEDALE SACRO CUORE-DON CALABRIA
    Full Title: Evaluation of Safety and Efficacy on Visual Acuity Outcome and Choroidal Neovascularization of Intravitreal Somministration of Bevacizumab Avastin, Roche, United Kingdom in patients with Subfovea...
    Medical condition: Subfoveal Choroidal Neovascularization due to Age Related Macular Degeneration who did not respond to currently available treatments
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060823 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000986-30 Sponsor Protocol Number: 140109 Start Date*: 2015-03-03
    Sponsor Name:IRCCS Ospedale San Raffaele U.O. Oculistica
    Full Title: Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)
    Medical condition: Choroidal neovascularization secondary to angioid streaks .
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008259-41 Sponsor Protocol Number: OZR-2008-20 Start Date*: 2009-03-30
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ...
    Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014854-14 Sponsor Protocol Number: CRFB002AGB10 Start Date*: 2009-11-17
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM)
    Medical condition: Choroidal neovascularisation (CNV) secondary to pathological myopia (PM)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    13.1 10015919 - Eye disorders 10067128 Myopic retinal degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001640-38 Sponsor Protocol Number: ATTRACT Start Date*: 2014-08-08
    Sponsor Name:CHU DE POITIERS
    Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization.
    Medical condition: Retinal diseases (type 3 choroidal neovascularization)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001453-28 Sponsor Protocol Number: CRFB002B2201 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly C...
    Medical condition: Male and female patients > 50 years of age with subfoveal choroidal neovascularization (CNV) secondary to AMD.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060837 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001781-15 Sponsor Protocol Number: IOBA-04-2012 Start Date*: 2012-07-31
    Sponsor Name:IOBA, Universidad de Valladolid
    Full Title: Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study)
    Medical condition: choroidal neovascularization associated to myopia magna
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022473-33 Sponsor Protocol Number: Protocol 21_07_2010 Start Date*: 2010-10-06
    Sponsor Name:Department of Ophthalmology, Hietzing Hospital
    Full Title: Short term effect of Lucentis® (Ranibizumab) as pretreatment to laser photocoagulation versus Lucentis® (Ranibizumab) combined with laser photocoagulation in the treatment of diabetic macular edema...
    Medical condition: Patients with macular edema due to diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006235-31 Sponsor Protocol Number: RET 03.07 Start Date*: 2007-09-13
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: 12 MONTHS CASE SERIES OPEN STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTION OF LUCENTIS (RANIBIZUMAB 0.5 MG) USED IN COMBINATION WITH VISUDYNE (VERTEPORFIN PDT) IN NAIVE SIBJECTS W...
    Medical condition: subfoveal choroidal neovascularization secondary to age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060823 Choroidal neovascularisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005056-15 Sponsor Protocol Number: AGO/2013/012 Start Date*: 2014-03-21
    Sponsor Name:UZ Gent
    Full Title: Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
    Medical condition: Choroidal neovascularisation and chronic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    21.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002245-12 Sponsor Protocol Number: EORTC 18021 Start Date*: 2005-01-27
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.
    Medical condition: Uveal melanomas with specific hepatic tropism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004172-12 Sponsor Protocol Number: CBPD952A2309 Start Date*: 2007-01-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Luc...
    Medical condition: Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001182-27 Sponsor Protocol Number: CRFB002ADE27 Start Date*: 2014-08-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003210-10 Sponsor Protocol Number: B0451001 Start Date*: 2009-09-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET...
    Medical condition: Subfoveal Choroidal Neovascularization (CNV) associated with Age-related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA